申请人:Dr. Karl Thomae GmbH
公开号:US04714698A1
公开(公告)日:1987-12-22
The invention relates to new compounds of general formula ##STR1## wherein R.sub.1 represents an alkyl group, R.sub.2 represents a hydrogen atom, an alkyl group optionally substituted (except at the .alpha. carbon atom) by a hydroxy group, or represents a cycloalkyl group or an allyl, phenyl or benzyl group, R.sub.3 represents an allyl group, an alkyl group optionally substituted (except at the .alpha. carbon atom) by a hydroxy group, or represents a cycloalkyl group or R.sub.2 and R.sub.3 together with the nitrogen atom between them represent a straight-chained alkyleneimino group, the acid addition salts thereof, particularly the acid addition salts thereof with physiologically acceptable inorganic or organic acids which have valuable pharmacological properties, particularly a metastasis-inhibiting effect based on their selective tumour-PDE inhibiting effect, and pharmaceutical compositions containing these compounds or the physiologically acceptable acid addition salts thereof. The new compounds may be prepared according to methods known for analogous compounds.
本发明涉及一种新的化合物,其一般式为##STR1##其中R.sub.1代表烷基基团,R.sub.2代表氢原子,一种烷基基团(除了α-碳原子处)可选择地被羟基基团取代,或代表环烷基团或烯丙基、苯基或苄基团,R.sub.3代表烯丙基团,一种烷基基团(除了α-碳原子处)可选择地被羟基基团取代,或代表环烷基团或R.sub.2和R.sub.3与它们之间的氮原子一起代表直链烷基亚胺基团,其酸加成盐,特别是与具有有价值的药理作用的生理上可接受的无机或有机酸的酸加成盐,特别是基于它们的选择性肿瘤-PDE抑制作用的转移抑制作用,以及含有这些化合物或其生理上可接受的酸加成盐的制药组合物。这些新化合物可以按类似化合物已知的方法制备。